Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium animalis subsp. lactis LAFTI B94 and Reduced Gastrointestinal Symptoms

Research synthesisLow evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 review-level studies, all report beneficial effects on gastrointestinal symptoms, with effect sizes ranging from small to moderate (two studies show moderate, one shows small). However, these reviews evaluate probiotics in general, not specifically Bifidobacterium animalis subsp. lactis LAFTI B94, and no primary RCTs with statistically significant findings were identified. The most studied population is athletes and recreationally active adults, but dose range and duration are not reported.

  • Studied populations: athletes and recreationally active adults

Caveats: No statistically significant findings reported; all evidence comes from reviews that may include multiple probiotic strains, not specifically LAFTI B94; dose and duration not reported; no primary human trials directly testing this strain for GI symptoms.

Generated May 11, 2026
3 of 3 papers
Back to top